INTRODUCTION

58
Human Immunodeficiency Virus type 1 (HIV-1) infection targets CD4-positive T-59 cells, macrophages, and other myeloid cells using CD4 and a chemokine co-receptor 60 (CCR5/CXCR4) (1). While CD4 T-cell loss is observed in tissue (2) and peripheral blood 61 (3, 4) during disease, loss of monocytes and macrophages is less evident. However, 62 monocyte activation, reflected in TLR/ISG-expression (5-9), monocyte subsets (10-12), 63 and soluble markers of activation (plasma sCD14, sCD163) (12-17) has been described 64 in both early and advanced HIV-1 disease. The impact of HIV-1 viremia on monocyte 5 monocyte apoptosis to identify functional changes relative to one another and viral load.
93
In addition, reports on anti-apoptotic responses in monocytes examined a limited range 94 of viral load (median viral load: 14,822 and 13,468 copies/mL, (18, 33) , respectively), 95 thus requiring a more extensive analysis across a wider viral load distribution.
96
Herein, we reconcile data between independent reports of pro-and anti-apoptotic 
MATERIALS AND METHODS
102
Donor population. HIV-1 seropositive patients (n=35, 11.4% female, median age=43.0 103 years) were recruited from the Hospital of the University of Philadelphia (HUP) and 
7
PCR was performed in a 20 μL reaction using Power SYBR Green PCR Master Mix 138 (Life Technologies) and custom designed primers (Inegrated DNA Technologies) ( Table   139 2) using the AB 7000 Sequence Detection System. The QuantumRNA Universal 18s
140
Internal Standard (Ambion) was used due to its robust and consistent expression across 141 all samples. All primer sets were assayed by serial dilution PCR across multiple donors on the independent variables and confirmed lack of multi-co-linearity in the final models 
RESULTS
202
Monocyte apoptosis is elevated in HIV-1 subjects with higher viremia.
203
Monocytes constitutive and induced apoptosis was examined in a cohort of 204 viremic patients ( group compared to controls ( Figure 3A , columns 1, 3), but did not detect differences 230 within the HIV(+) groups ( Figure 3B ) or an association between these variables with 231 viral load ( Figure 3C ), monocyte apoptosis ( Figure 3D ), or CD4 count (Supplemental 232 Figure 2 ). Conversely, plasma sCD14 concentration was associated with viral load
233
( Figure 3C ) and CD4 count (Supplemental Figure 2A ), but not monocyte apoptosis
234
( Figure 3D , p=0.1070). Below a CD4 count of 500 cells/mm 3 (Supplemental Figure 2B) 
DISCUSSION
285
Here we show for the first time that monocyte apoptosis is elevated in patients 286 with greater than 40,000 copies/mL and negatively associated with CD4 count ( Figure   287 2). Our data suggest that a viral load below this threshold can modulate monocytes and 288 macrophages activation as indicated by change in sCD163 and CD14+/CD16+
289
monocytes, yet does not result in a rise in apoptosis until higher viral loads, clarifying 290 conflicting reports of monocyte apoptosis in HIV infection (18, 30-33, 35, 41) .
291
Interestingly, our data suggests the presence of at least two distinct phases of 292 monocyte/macrophage activation relative to viremia: (1) below 40,000 copies/mL, 293 characterized by increases in plasma sCD163, the CD14+/16+ intermediate monocyte
294
subset, Rb1 expression, and cell viability (as described in (18, 32, 33)), and (2) above 295 40,000 copies/mL, described here, characterized by increasing plasma sCD14 with viral 296 load, high ISG expression, and elevated apoptosis.
14 Although monocyte type-1 interferon-stimulated gene expression (7, 8, 19) 
306
Previous studies have demonstrated elevated sCD14 in multiple HIV(+) to HIV(-) 307 donor comparisons (14, 16, 17, (66) (67) (68) , and while we demonstrate an association with Figure 5 ) and IFITM2 and Rb1 were present in both models ( 
